Intuitive Surgical

TCW's Q2 2026 investor letter highlights Intuitive Surgical, noting solid quarterly results, revenue and Da Vinci procedure growth above estimates, but weaker system placements in China and Japan. ISRG repurchased 2.3M shares for $1.1B in 1Q26 and management raised 2026 guidance, yet shares have lagged amid negative sentiment toward medtech and high-growth multiples. TCW expects further penetration from the early rollout of Da Vinci 5 and cites a 20-year lead and strong competitive moat, remaining constructive on the stock. » More on finance.yahoo.com

Intuitive Surgical's stock has fallen about 33% in 2026 amid concerns over competition from China and potential AI disruption, yet its forward P/E near 35 is well below the five-year average. The company has an installed base of over 12,000 systems across 70+ countries and recurring revenue from instruments and services makes up roughly 75% of sales. Fund managers and most analysts still expect mid-teens revenue growth and view the lower share price as a buying opportunity for long-term, risk-tolerant investors. » More on finance.yahoo.com

Intuitive Surgical’s stock rose in premarket trading after Oppenheimer upgraded it to “Outperform” with a $500 price target; at the same time Bank of America issued a buy recommendation. Earlier upgrades from UBS and Morgan Stanley and Q2 earnings per share of $2.80 (consensus $2.51) support the re-rating. Analysts note competitors face short-term structural hurdles and that the da Vinci system dominates about 83% of the market. Routine 10b5-1 insider sales are not being viewed as a negative signal; the premarket price of around $404.51 remains below the 52-week high of $603.88. » More on de.investing.com